Equities Analysts Offer Predictions for Boston Scientific Corporation’s FY2018 Earnings (BSX)

Boston Scientific Corporation (NYSE:BSX) – Equities research analysts at Oppenheimer Holdings raised their FY2018 EPS estimates for shares of Boston Scientific Corporation in a note issued to investors on Tuesday. Oppenheimer Holdings analyst S. Lichtman now forecasts that the medical equipment provider will post earnings of $1.39 per share for the year, up from their previous estimate of $1.38. Oppenheimer Holdings currently has a “Hold” rating on the stock.

Boston Scientific Corporation (NYSE:BSX) last issued its earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 EPS for the quarter, meeting the consensus estimate of $0.31. The company had revenue of $2.22 billion during the quarter, compared to analysts’ expectations of $2.21 billion. Boston Scientific Corporation had a net margin of 9.55% and a return on equity of 23.60%. The business’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period in the previous year, the company earned $0.27 EPS.

COPYRIGHT VIOLATION NOTICE: This article was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://sportsperspectives.com/2017/11/11/equities-analysts-offer-predictions-for-boston-scientific-corporations-fy2018-earnings-bsx.html.

A number of other equities analysts have also recently issued reports on the stock. BidaskClub cut shares of Boston Scientific Corporation from a “hold” rating to a “sell” rating in a research report on Saturday, August 26th. Royal Bank Of Canada reiterated a “buy” rating and set a $31.00 price objective on shares of Boston Scientific Corporation in a research report on Friday, September 1st. Jefferies Group LLC reiterated a “hold” rating on shares of Boston Scientific Corporation in a research report on Thursday, September 7th. Stifel Nicolaus reiterated a “buy” rating and set a $32.00 price objective on shares of Boston Scientific Corporation in a research report on Sunday, July 30th. Finally, Zacks Investment Research upgraded shares of Boston Scientific Corporation from a “sell” rating to a “buy” rating and set a $33.00 price target for the company in a research report on Friday, October 20th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. Boston Scientific Corporation has an average rating of “Buy” and a consensus target price of $30.77.

Shares of Boston Scientific Corporation (NYSE BSX) traded down $0.23 during trading hours on Thursday, hitting $28.36. 6,526,000 shares of the stock traded hands, compared to its average volume of 6,648,832. The firm has a market cap of $39,259.68, a PE ratio of 23.43, a PEG ratio of 2.21 and a beta of 1.00. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58. Boston Scientific Corporation has a one year low of $19.67 and a one year high of $29.93.

In other Boston Scientific Corporation news, SVP Maulik Nanavaty sold 57,031 shares of the stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $27.28, for a total transaction of $1,555,805.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael P. Phalen sold 15,500 shares of the stock in a transaction dated Tuesday, August 29th. The stock was sold at an average price of $26.87, for a total transaction of $416,485.00. The disclosure for this sale can be found here. Insiders have sold 508,864 shares of company stock valued at $14,581,669 in the last quarter. Company insiders own 0.74% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Acrospire Investment Management LLC boosted its position in shares of Boston Scientific Corporation by 157.3% in the second quarter. Acrospire Investment Management LLC now owns 5,071 shares of the medical equipment provider’s stock valued at $141,000 after acquiring an additional 3,100 shares during the period. Bronfman E.L. Rothschild L.P. boosted its position in shares of Boston Scientific Corporation by 14.3% in the second quarter. Bronfman E.L. Rothschild L.P. now owns 5,761 shares of the medical equipment provider’s stock valued at $160,000 after acquiring an additional 720 shares during the period. San Francisco Sentry Investment Group CA bought a new position in shares of Boston Scientific Corporation in the second quarter valued at approximately $191,000. Ironwood Investment Counsel LLC bought a new position in shares of Boston Scientific Corporation in the third quarter valued at approximately $204,000. Finally, Perkins Capital Management Inc. bought a new stake in Boston Scientific Corporation during the third quarter valued at approximately $204,000. Institutional investors own 90.45% of the company’s stock.

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Earnings History and Estimates for Boston Scientific Corporation (NYSE:BSX)

Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply